<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Pharmateca</journal-id><journal-title-group><journal-title xml:lang="en">Pharmateca</journal-title><trans-title-group xml:lang="ru"><trans-title>Фарматека</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2073-4034</issn><issn publication-format="electronic">2414-9128</issn><publisher><publisher-name xml:lang="en">Bionika Media</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">380896</article-id><article-id pub-id-type="doi">10.18565/pharmateca.2025.10.39-44</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Clinical experience</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Клинический опыт</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Current principles of antibiotic therapy in the management of patients with chlamydial infection</article-title><trans-title-group xml:lang="ru"><trans-title>Актуальные принципы антибиотикотерапии при ведении пациентов с хламидийной инфекцией</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-5044-5265</contrib-id><name-alternatives><name xml:lang="en"><surname>Kruglova</surname><given-names>Larisa S.</given-names></name><name xml:lang="ru"><surname>Круглова</surname><given-names>Лариса Сергеевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Dr. Sci. (Med.), Professor, Head of the Department of Dermatovenereology and Cosmetology, Rector</p></bio><bio xml:lang="ru"><p>д.м.н., профессор, зав. кафедрой дерматовенерологии и косметологии, ректор</p></bio><email>kruglovals@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-5245-0394</contrib-id><name-alternatives><name xml:lang="en"><surname>Rubtsova</surname><given-names>Lyubov A.</given-names></name><name xml:lang="ru"><surname>Рубцова</surname><given-names>Любовь Алексеевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>lubovrubtz@gmail.com</email><xref ref-type="aff" rid="aff3"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-3190-7460</contrib-id><name-alternatives><name xml:lang="en"><surname>Kruglova</surname><given-names>Maria S.</given-names></name><name xml:lang="ru"><surname>Круглова</surname><given-names>Мария Сергеевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>kruglovamashulka@gmail.com</email><xref ref-type="aff" rid="aff5"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Central State Medical Academy of the Administrative Directorate of the President of the Russian Federation</institution></aff><aff><institution xml:lang="ru">Центральная государственная медицинская академия Управления делами Президента РФ</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en"></institution></aff><aff><institution xml:lang="ru">Центральная государственная медицинская академия Управления делами Президента РФ</institution></aff></aff-alternatives><aff-alternatives id="aff3"><aff><institution xml:lang="en">Central State Medical Academy of the Administrative Directorate of the President of the Russian Federation</institution></aff><aff><institution xml:lang="ru">Институт пластической хирургии и косметологии</institution></aff></aff-alternatives><aff-alternatives id="aff4"><aff><institution xml:lang="en">Institute of Plastic Surgery and Cosmetology</institution></aff><aff><institution xml:lang="ru">Первый Московский государственный медицинский университет им. И.М. Сеченова (Сеченовский университет)</institution></aff></aff-alternatives><aff id="aff5"><institution>I.M. Sechenov First Moscow State Medical University (Sechenov University)</institution></aff><pub-date date-type="pub" iso-8601-date="2025-12-31" publication-format="electronic"><day>31</day><month>12</month><year>2025</year></pub-date><volume>32</volume><issue>10</issue><fpage>39</fpage><lpage>44</lpage><history><date date-type="received" iso-8601-date="2026-02-03"><day>03</day><month>02</month><year>2026</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2025, Bionika Media</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2025, ООО «Бионика Медиа»</copyright-statement><copyright-year>2025</copyright-year><copyright-holder xml:lang="en">Bionika Media</copyright-holder><copyright-holder xml:lang="ru">ООО «Бионика Медиа»</copyright-holder></permissions><self-uri xlink:href="https://journals.rcsi.science/2073-4034/article/view/380896">https://journals.rcsi.science/2073-4034/article/view/380896</self-uri><abstract xml:lang="en"><p>Given the increasing global incidence of urogenital chlamydial infection caused by Chlamydia trachomatis and the challenges of its diagnosis, choosing an effective therapy is particularly important. Currently, doxycycline is the first-line drug, supported by its pharmacokinetic advantages: its ability to create and maintain long-term concentrations in the tissues of the urogenital tract and rectum necessary for successful eradication of the pathogen. High efficacy, favorable tolerability profile, and ability to treat extragenital foci of infection make Doxycycline EXPRESS the drug of choice for the treatment and post-exposure prophylaxis of chlamydial infection.</p></abstract><trans-abstract xml:lang="ru"><p>В условиях роста глобальной заболеваемости урогенитальным хламидиозом, вызываемым Chlamydia trachomatis, и в связи с проблемами его диагностики особую актуальность приобретает выбор эффективной терапии. В настоящее время препаратом первой линии является доксициклин, что подтверждается его фармакокинетическими преимуществами: способностью создавать и длительно поддерживать в тканях урогенитального тракта и прямой кишки концентрации, необходимые для успешной эрадикации возбудителя. Высокая эффективность, благоприятный профиль переносимости и способность санировать экстрагенитальные очаги инфекции делают Доксициклин ЭКСПРЕСС средством выбора для терапии и постконтактной профилактики хламидийной инфекции.</p></trans-abstract><kwd-group xml:lang="en"><kwd>chlamydial infection</kwd><kwd>antibiotic therapy</kwd><kwd>doxycycline</kwd><kwd>Doxycycline EXPRESS</kwd><kwd>doxycycline monohydrate</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>хламидийная инфекция</kwd><kwd>антибиотикотерапия</kwd><kwd>доксициклин</kwd><kwd>Доксициклин ЭКСПРЕСС</kwd><kwd>доксициклина моногидрат</kwd></kwd-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>World Health Organization. Sexually transmitted infections (STIs): fact sheet. 2023. URL: https://www.who.int/news-room/fact-sheets/detail/sexually-transmitted-infections-(stis) (accessed: 15.10.2024).</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>О состоянии санитарно-эпидемиологического благополучия населения в Российской Федерации в 2023 году: Государственный доклад. Федеральная служба по надзору в сфере защиты прав потребителей и благополучия человека (Роспотребнадзор). М., 2024. 300 с. [On the state of sanitary and epidemiological well-being of the population in the Russian Federation in 2023: State report. Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing (Rospotrebnadzor). Moscow, 2024. 300 p. (In Russ.)].</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Unemo M., Bradshaw C.S., Hocking J.S. Sexually transmitted infections: challenges ahead. Lancet Infect Dis. 2017;17(8):e235-e279. https://dx.doi.org/10.1016/S1473-3099(17)30310-9</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Workowski K.A., Bachmann L.H., Chan P.A. Sexually Transmitted Infections Treatment Guidelines, 2021. MMWR Recomm Rep. 2021;70(4):1-187. https://dx.doi.org/10.15585/mmwr.rr7004a1</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Cunningham K.A., Beagley K.W. Male genital tract chlamydial infection: implications for pathology and infertility. Biol Reprod. 2008;79(2):180-189. https://dx.doi.org/10.1095/biolreprod.108.067835</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Хламидийная инфекция. Клинические рекомендации Минздрава РФ. 2024. 42 с. [Chlamydial infection. Clinical guidelines of the Ministry of Health of the Russian Federation. 2024. 42 p. (In Russ.)].</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Воспалительные болезни женских тазовых органов. Клинические рекомендации Миндзрава РФ. 2024. 49 с. [Inflammatory diseases of the female pelvic organs. Clinical guidelines of the Ministry of Health of the Russian Federation. 2024. 49 p. (In Russ.)].</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Chlamydia control in Europe: evidence-based guidance for public health authorities. European Centre for Disease Prevention and Control (ECDC). – Stockholm: ECDC, 2022. URL: https://www.ecdc.europa.eu/en/publications-data/chlamydia-control-europe-evidence-based-guidance-public-health-authorities (accessed: 15.10.2024).</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Agwuh K.N., MacGowan A. Pharmacokinetics and pharmacodynamics of the tetracyclines including glycylcyclines. J Antimicrob Chemother. 2006;58(2):256-265. https://dx.doi.org/10.1093/jac/dkl224</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Спичак И.В., Нефедова А.В. Современные аспекты фармакотерапии урогенитального хламидиоза: фокус на комплаенс. Антибиотики и химиотерапия. 2022;67(1-2):45-52. [Spichak I.V., Nefedova A.V. Modern aspects of pharmacotherapy of urogenital chlamydia: focus on compliance. Antibiotics and chemotherapy. 2022;67(1-2):45-52. (In Russ.)].</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Rowley J., Hoorn S.V., Korenromp E. Chlamydia, gonorrhoea, trichomoniasis and syphilis: global prevalence and incidence estimates, 2016. Bull World Health Organ. 2019;97(8):548-562. https://dx.doi.org/10.2471/BLT.18.228486</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Haaland R.E., Bader A.M., Domogala D. Pharmacokinetics of single dose doxycycline in the rectum, vagina, and urethra: implications for prevention of bacterial sexually transmitted infections. EBioMedicine. 2024;101:104990. https://dx.doi.org/10.1016/j.ebiom.2024.104990.https://doi.org/10.1016/j.ebiom.2024.105037</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Workowski K.A., Bachmann L.H. Centers for Disease Control and Prevention’s sexually transmitted diseases infection guidelines. Clin Infect Dis. 2022;74(Suppl. 2):S89-S94. https://dx.doi.org/10.1093/cid/ciac043.https://doi.org/10.1093/cid/ciab1055</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Sokoll P.R., Vanhove A., Wesson P. Efficacy of postexposure prophylaxis with doxycycline (Doxy-PEP) in reducing sexually transmitted infections: a systematic review and meta-analysis. Sex Transm Infect. 2025;101(1):59-67. https://doi.org/10.1136/sextrans-2024-056208</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Dukers-Muijrers N.H.T.M., Schachter J., Wolffs P.F.G. Controversies and evidence on Chlamydia testing and treatment in asymptomatic women and men who have sex with men: a narrative review. BMC Infect Dis. 2022;22(1):255. https://dx.doi.org/10.1186/s12879-022-07173-0</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Mohammadzadeh F., Dolatian M., Jorjani M. Urogenital Chlamydia trachomatis treatment failure with azithromycin: A meta-analysis. Int J Reprod Biomed. 2019;17(9):603-620. https://dx.doi.org/10.18502/ijrm.v17i9.5093</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Dombrowski J.C., Wierzbicki M.R., Newman L.M. Doxycycline Versus Azithromycin for the Treatment of Rectal Chlamydia in Men Who Have Sex With Men: A Randomized Controlled Trial. Clin Infect Dis. 2021;73(5):824-831. https://dx.doi.org/10.1093/cid/ciab153</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Lau A., Kong F.Y.S., Fairley C.K. Azithromycin or Doxycycline for Asymptomatic Rectal Chlamydia trachomatis. N Engl J Med. 2021;384(25):2418-2427. https://dx.doi.org/10.1056/NEJMoa2031631</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Peuchant O., Lhomme E., Krêt M. Randomized, open-label, multicenter study of azithromycin compared with doxycycline for treating anorectal Chlamydia trachomatis infection concomitant to a vaginal infection (CHLAZIDOXY study). Medicine (Baltimore). 2019;98(7):e14572. https://dx.doi.org/10.1097/MD.0000000000014572</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Dukers-Muijrers N., Wolfs P.F.G., De Vries H. Treatment effectiveness of azithromycin and doxycycline in uncomplicated rectal and vaginal Chlamydia trachomatis infections in women: a multicenter observational study (FemCure). Clin Infect Dis. 2019;69(11):1946–1954. https://dx.doi.org/10.1093/cid/ciz050</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Peuchant O., Lhomme E., Martinet P. Doxycycline versus azithromycin for the treatment of anorectal Chlamydia trachomatis infection in women concurrent with vaginal infection (CHLAZIDOXY study): a multicentre, open-label, randomised, controlled, superiority trial. Lancet Infect Dis. 2022;22(8):1221-1230. https://dx.doi.org/10.1016/S1473-3099(22)00148-7</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Páez-Canro C., Alzate J.P., González L.M. Antibiotics for treating urogenital Chlamydia trachomatis infection in men and non-pregnant women. Cochrane Database System Rev. 2019;1:CD010871. https://dx.doi.org/10.1002/14651858.CD010871.pub2</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Dukers-Muijrers N.H.T.M., Wolfs P.F.G., de Vries H.J.C. Viable bacterial load is key to azithromycin treatment failure in rectally Chlamydia trachomatis infected women (FemCure). J Infect Dis. 2019;220(8):1389–1390. https://dx.doi.org/10.1093/infdis/jiz321</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Dukers-Muijrers N., Janssen K.J.H., Hoebe C. Spontaneous clearance of Chlamydia trachomatis accounting for bacterial viability in vaginally or rectally infected women (FemCure). Sex Transm Infect. 2020;96(7):541–548. https://dx.doi.org/10.1136/sextrans-2019-054310</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Janssen K.J.H., Wolfs P.F.G., Hoebe C. Determinants associated with viable genital or rectal Chlamydia trachomatis bacterial load (FemCure). Sex Transm Infect. 2021;98(1):17–22. https://dx.doi.org/10.1136/sextrans-2020-054819</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>Dukers-Muijrers N., Schim van der Loeff M., Wolfs P. Incident urogenital and anorectal Chlamydia trachomatis in women: the role of sexual exposure and autoinoculation: a multicentre observational study (FemCure). Sex Transm Infect. 2022;98(6):391-396. https://dx.doi.org/10.1136/sextrans-2021-055032</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation>Tamarelle J., Penaud B., Tyssandier B. Effects of azithromycin and doxycycline on the vaginal microbiota of women with urogenital Chlamydia trachomatis infection: a substudy of the Chlazidoxy randomized controlled trial. Clin Microbiol Infect. 2023;29(8):1056-1062. https://dx.doi.org/10.1016/j.cmi.2023.04.020</mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation>Tamarelle J., Ma B., Gajer P. Nonoptimal vaginal microbiota after azithromycin treatment for Chlamydia trachomatis infection. J Infect Dis. 2020;221(4):627-635. https://dx.doi.org/10.1093/infdis/jiz499</mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation>Käding N., Schmidt N., Scholz C. Impact of First-Line Antimicrobials on Chlamydia trachomatis-Induced Changes in Host Metabolism and Cytokine Production. Front Microbiol. 2021;12:676747. https://dx.doi.org/10.3389/fmicb.2021.676747</mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation>Yetkin-Arik B., Vogels I.M.C., Nowak-Sliwinska P. The role of glycolysis and mitochondrial respiration in the formation and functioning of endothelial tip cells during angiogenesis. Sci Rep. 2019;9:12608. https://dx.doi.org/10.1038/s41598-019-48676-2</mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation>Shima K., Kaufhold I., Eder T. Regulation of the mitochondrion-fatty acid axis for the metabolic reprogramming of Chlamydia trachomatis during treatment with β-lactam antimicrobials. mBio. 2021;12(2):e00023-21. https://dx.doi.org/10.1128/mBio.00023-21</mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation>URL: https://www.vidal.ru/drugs/doxycycline-express?ysclid=mj7gag0bl5935524061</mixed-citation></ref><ref id="B33"><label>33.</label><mixed-citation>Аль-Шукри А.С., Коломийцева М.Р., Петров С.Б. Доксициклин в лечении инфекций мочевыводящих путей. Consilium Medicum. 2024;26(7):471–477. [Al-Shukri A.S., Kolomiytseva M.R., Petrov S.B. Doxycycline in the treatment of urinary tract infections. Consilium Medicum. 2024;26(7):471–477. (In Russ.)].</mixed-citation></ref></ref-list></back></article>
